Section of Gastroenterology and Hepatology, Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Departments of Epidemiology and Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire; University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Cancer Prev Res (Phila). 2019 May;12(5):295-304. doi: 10.1158/1940-6207.CAPR-19-0023. Epub 2019 Mar 4.
Vitamin D and calcium supplementation are postulated to have chemopreventive effects against colorectal neoplasia, yet in our previously reported randomized trial, there was no overall efficacy of calcium and/or vitamin D against colorectal adenoma recurrence. It is possible vitamin D and calcium chemopreventive effects are not detectable until beyond the 3- to 5-year follow-up captured in that trial. Accordingly, we explored possible vitamin D and calcium effects on posttreatment (observational) adenoma occurrence. In this secondary analysis of the observational follow-up phase of the Vitamin D/Calcium Polyp Prevention Study, participants who completed the treatment phase were invited to be followed for one additional surveillance colonoscopy cycle. We evaluated adenoma occurrence risk at surveillance colonoscopy, with a mean of 55 ± 15 months after treatment follow-up, according to randomized treatment with vitamin D versus no vitamin D, calcium versus no calcium, and calcium plus vitamin D versus calcium alone. Secondary outcomes included advanced and multiple adenomas. Among the 1,121 participants with observational follow-up, the relative risk (95% confidence interval, CI) of any adenoma was 1.04 (0.93-1.17) for vitamin D versus no vitamin D; 0.95 (0.84-1.08) for calcium versus no calcium; 1.07 (0.91-1.25) for calcium plus vitamin D versus calcium; and 0.96 (0.81-1.15) for calcium plus vitamin D versus neither. Risks of advanced or multiple adenomas also did not differ by treatment. Our results do not support an association between supplemental calcium and/or vitamin D for 3 to 5 years and risk of recurrent colorectal adenoma at an average of 4.6 years after treatment.
维生素 D 和钙补充剂被认为对结直肠肿瘤具有化学预防作用,但在我们之前报道的随机试验中,钙和/或维生素 D 对结直肠腺瘤复发没有总体疗效。有可能直到试验中捕获的 3 至 5 年随访之后,才能检测到维生素 D 和钙的化学预防作用。因此,我们探讨了维生素 D 和钙对治疗后(观察性)腺瘤发生的可能影响。在维生素 D/钙息肉预防研究的观察性随访阶段的二次分析中,完成治疗阶段的参与者被邀请再接受一次结肠镜监测。我们根据维生素 D 与无维生素 D、钙与无钙、钙加维生素 D 与钙单独治疗的随机治疗,评估了治疗后随访 55 ± 15 个月时结肠镜监测下的腺瘤发生风险。次要结局包括高级别和多发性腺瘤。在 1121 名接受观察性随访的参与者中,维生素 D 与无维生素 D 相比,任何腺瘤的相对风险(95%置信区间,CI)为 1.04(0.93-1.17);钙与无钙相比,0.95(0.84-1.08);钙加维生素 D 与钙相比,1.07(0.91-1.25);钙加维生素 D 与两者均无相比,0.96(0.81-1.15)。治疗组之间高级别或多发性腺瘤的风险也没有差异。我们的结果不支持在治疗后 3 至 5 年内补充钙和/或维生素 D 与结直肠腺瘤复发风险之间存在关联,平均在治疗后 4.6 年。